GlassScriptPhysician profile
Carl Demidovich
NPI 1558463307
$12,928.30
in general payments reported to CMS, 2019-2025
39 companies · $1,268 in 2025
The $1,268 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,947 · 2020: $854 · 2021: $1,901 · 2022: $2,233 · 2023: $1,721 · 2024: $2,005 · 2025: $1,268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,978 · Education: $15.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,978.17 |
| Education | $15.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,007.69 | 2019-2025 | Skyrizi, Rinvoq |
| Biofrontera INC. | $1,292.59 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Genzyme Corporation | $1,228.04 | 2019-2025 | |
| Janssen Biotech, INC. | $1,044.08 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Regeneron Healthcare Solutions, INC. | $805.46 | 2019-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $673.81 | 2019-2025 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $668.15 | 2019-2024 | Jublia, Cabtreo |
| Sun Pharmaceutical Industries INC. | $594.33 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $587.35 | 2019-2025 | |
| Pfizer INC. | $561.60 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $525.65 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $507.91 | 2019-2025 | Taltz, Olumiant, Zepbound |
| Amgen INC. | $329.61 | 2019-2025 | Otezla, Otezla |
| Incyte Corporation | $316.27 | 2021-2025 | Opzelura |
| Almirall LLC | $297.83 | 2019-2021 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $196.82 | 2019-2025 | Aklief, Nemluvio |
| Ucb, INC. | $184.80 | 2021-2025 | Bimzelx |
| Allergan, INC. | $123.49 | 2019 | |
| Organogenesis INC. | $111.12 | 2023-2025 | Novachor, Puraply Wound Matrix, Puraply |
| Journey Medical Corporation | $102.82 | 2019 | |
| Janssen Scientific Affairs, LLC | $101.48 | 2019 | |
| Genentech USA, INC. | $70.78 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $58.63 | 2020-2021 | |
| Kerecis Limited | $58.58 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Arcutis Biotherapeutics, INC. | $56.96 | 2023-2024 | Zoryve |
| Mylan Pharmaceuticals INC. | $56.46 | 2019 | |
| Dermira, INC. | $50.42 | 2019-2020 | |
| Epi Health, LLC | $42.74 | 2019-2020 | |
| Celgene Corporation | $38.68 | 2019 | |
| Ani Pharmaceuticals, INC. | $38.18 | 2022 | |
| Merz North America, INC. | $36.61 | 2019-2020 | |
| Organon LLC | $34.54 | 2024-2025 | Vtama |
| Dusa Pharmaceuticals, INC. | $22.86 | 2019 | |
| Misonix INC | $18.61 | 2020 | |
| Mission Pharmacal Company | $18.46 | 2019 | |
| Kyowa Kirin, INC. | $17.92 | 2022 | |
| Dilon Technologies, INC. | $17.56 | 2024 | Hemoblast Bellows |
| Verrica Pharmaceuticals INC. | $17.47 | 2023 | Ycanth |
| Merck Sharp & Dohme LLC | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Demidovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.